Fibrinogen heterogeneity in horses

Elise B. Russell | Natalie F. Courtman | Leilani L. Santos | Brett S. Tennent-Brown

U-Vet Werribee Animal Hospital and Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, Victoria, Australia

Correspondence
Brett S. Tennent-Brown, U-Vet Werribee Animal Hospital and Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, VIC, Australia.
Email: brett.tennent@unimelb.edu.au

Funding information
University of Melbourne

Abstract

Background: Fibrinogen heterogeneity has been observed in humans and can influence fibrinogen measurements when using the modified Clauss assay. We hypothesized that fibrinogen heterogeneity also exists in horses.

Objectives: To determine whether fibrinogen heterogeneity exists in horses.

Animals: Five clinically healthy horses from the university equine teaching herd.

Methods: Presumed fibrinogen was purified from pooled citrated plasma and electrophoresis performed. The purified protein was subjected to Western blotting using sheep antiserum against human fibrinogen, and liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Results: Gel electrophoresis of nonreduced equine purified protein yielded 2 protein bands (approximately 377 and 318 kDa) that corresponded with the molecular weights of human high molecular weight fibrinogen and low molecular weight fibrinogen fractions, respectively. Electrophoretograms of reduced purified protein, Western blots, and LC-MS/MS supported that the purified nonreduced protein bands were fibrinogen.

Conclusion: Fibrinogen heterogeneity exists in horses.

KEYWORDS
citrate, EDTA, equine, fibrinogen variants, high molecular weight fibrinogen, low molecular weight fibrinogen, protein purification, Vila method

1 | INTRODUCTION

Fibrinogen plays a critical role in coagulation and wound healing in humans and other animals. In equine medicine, measurement of plasma fibrinogen concentration is an inexpensive and widely available tool used for the detection of inflammation. Fibrinogen is a dimer with each half-molecule composed of A, Bβ, and γ polypeptide subunits. Human fibrinogen exists in 3 forms: high molecular weight fibrinogen (HMW-Fb), low molecular weight fibrinogen (LMW-Fb), and very low molecular weight fibrinogen (LMW-Fb), with molecular weights of approximately 340 kDa, 305 kDa, and 270 kDa, respectively.2,3 The LMW- and LMW0-Fb are derived from HMW-Fb by proteolytic cleavage of the C-terminus of the Aα polypeptide subunit,4,5 but the exact mechanism of this degradation remains unknown.6 In healthy humans, the mean proportions of the fibrinogen fractions are 70% HMW-Fb, 26% LMW-Fb, and 4% LMW0-Fb.2,3 These proportions are altered in certain disease states,2,4,7-9 and can have prognostic utility.10

In veterinary medicine, total fibrinogen measurement now is commonly performed using the modified Clauss method,11 which has largely superseded heat precipitation tests such as the Millar method.12

In the modified Clauss method, highly concentrated thrombin is added to diluted patient plasma, and the time to clot formation is compared to a reference standard. The modified Clauss method is simple, rapid, and reliable and is considered the standard laboratory method for fibrinogen.13 However, the modified Clauss method is known to be influenced by fibrinogen heterogeneity.14,15

In human medicine, fibrinogen heterogeneity has been observed when using the modified Clauss method.16,17 Several studies have shown that fibrinogen heterogeneity can lead to falsely low fibrinogen measurements when using the modified Clauss assay,16,18-20 potentially leading to an underdiagnosis of inflammation.19

In equine medicine, fibrinogen heterogeneity also exists.16 The use of the modified Clauss method to measure fibrinogen concentration may lead to falsely low fibrinogen measurements in horses, which could result in an underdiagnosis of inflammation in these animals. Therefore, the aim of this study was to determine whether fibrinogen heterogeneity exists in horses.
to a standard to curve to obtain the total fibrinogen concentration.\textsuperscript{13} In human medicine, total fibrinogen concentrations measured by the Clauss method are higher in citrated samples than in ethylenediaminetetraacetic acid (EDTA) samples.\textsuperscript{9} This discrepancy has been hypothesized to be a result of magnesium ion chelation in EDTA samples. Magnesium ions are thought to be required for optimal clot formation from LMW-Fb and LMW-Fb and in EDTA samples, these fractions might be unable to contribute to clot formation, prolonging clotting times and lowering the total measured fibrinogen concentration.\textsuperscript{9} Similar discrepancies in measured fibrinogen concentrations between citrated and EDTA plasma samples have been observed in our laboratory in equine samples, prompting us to question whether lower molecular weight fibrinogen fractions might also exist in horses.

We aimed to determine whether fibrinogen heterogeneity exists in equine plasma.

2 | MATERIALS AND METHODS

2.1 | Samples

The use of blood samples collected from our equine teaching herd was approved by the institutional animal ethics committee (ID 1714380.2).

Whole blood was collected by jugular venipuncture from 5 healthy adult horses (2 Standardbred mares, 1 Thoroughbred mare, and 2 Thoroughbred geldings) from the university’s teaching herd. Horses were considered healthy and suitable for study enrollment if they had normal physical examination findings; total fibrinogen concentration (measured by the modified Clauss method in citrated plasma) within the reference interval (RI) established in our laboratory using 71 healthy thoroughbred geldings; and normal CBC (Sysmex XN-1000, Sysmex Corporation, Kobe, Japan) and blood film cytology results (assessed by E.B. Russell; a third year clinical pathology resident).

Samples were collected into two 3.2% sodium citrate blood tubes and 2 gel-activated clot tubes (Vacuette tubes, Greiner Bio-One GmbH, Kremsmünster, Austria) from each horse. Samples were immediately chilled, centrifuged at 1500g at 4°C for 15 minutes within 30 minutes of collection, with the obtained serum and plasma separated and pooled.

2.2 | Purification of fibrinogen from equine plasma

Purification of fibrinogen from equine plasma was performed using a modified Vila method.\textsuperscript{14} Precipitation of 400 µL of plasma was achieved by adding an equal volume of 80 g/L polyethylene glycol (PEG), \( M_w = 6000 \). The plasma-PEG mixture was placed in an ice bath, gently agitated for 10 minutes and then centrifuged at 1200g at 4°C for 7 minutes. The resulting precipitate was re-dissolved in 400 µL of 0.01 M phosphate-buffered saline (PBS), pH 7.4 (P3813, Sigma-Aldrich Pty. Ltd, Sydney, Australia) and then precipitated again by the addition of 800 µL of 2 M acetic acid-acetate buffer, pH 4.6. This mixture was placed back into an ice bath, gently agitated for 30 minutes and then centrifuged at 1200g at 4°C for 7 minutes. The resultant precipitate was once again dissolved in 400 µL of 0.036 M PBS, pH 7.8 with 200 000 kallikrein inhibitor units (KIU)/L aprotinin. The sample then was precipitated by the addition of 133 µL of 4 M ammonium sulfate followed by centrifugation at 1200g at 4°C for 7 minutes. The final precipitate was re-dissolved in 400 µL of 0.018 M PBS, pH 7.8 with 200 000 KIU/L aprotinin. To create negative control samples for Western blotting, the purification procedure was performed simultaneously on 400 µL of pooled serum.

2.3 | Gel electrophoresis of purified horse protein

Protein concentrations in purified plasma and serum samples were estimated using a commercial colorimetric assay\textsuperscript{15} (Pierce BCA Protein Assay Kit, Thermo Scientific, Scoresby, Australia), in accordance with the manufacturer’s directions.

Purified (presumptive) fibrinogen was subjected to electrophoresis in a nonreduced form to evaluate for the presence of fibrinogen heterogeneity (ie, the existence of high and low molecular weight fractions). Purified fibrinogen also was subjected to electrophoresis after reduction to ensure that the protein was comprised of the expected fibrinogen subunits \((\alpha_x, \beta, \gamma)\). For the nonreduced sample, 4 µg/µL purified pooled horse fibrinogen in 1× Laemmli sample buffer (Bio-Rad, Gladesville, Australia) was heated to 70°C for 10 minutes, then subjected to electrophoresis using tris-acetate sodium dodecyl sulfate (SDS) running buffer (NuPAGE Tris-Acetate SDS Running Buffer, Thermo Scientific) on a 3% to 8% tris-acetate polyacrylamide gel electrophoresis (PAGE) gel (NuPAGE Tris-Acetate Protein Gels, Thermo Scientific) for 55 minutes at 150 V (constant). For the reduced sample, 4 µg/µL purified pooled equine fibrinogen in 1× Laemmli sample buffer with 355 mM 2-mercaptoethanol (Bio-Rad) was heated to 100°C for 5 minutes, then subjected to electrophoresis using tris-glycine running buffer (Bio-Rad) on an 8% to 16% tris-glycine PAGE gel (Mini-Protein TGX Precast Protein Gels, Bio-Rad) for 45 minutes at 150 V (constant). For both reduced and nonreduced samples, prestained protein standards (HiMark Pre-stained protein standard, Thermo Scientific and Precision Plus Protein Dual Color protein standard, Bio-Rad) were included for molecular weight estimation, 3 µg of human fibrinogen (Sigma-Aldrich Pty. Ltd) was included as a positive control, and purified pooled equine serum (7.5 µL) and nonpurified pooled equine serum (3 µg) were included as negative controls. Purified pooled equine serum (treated identically to the purified plasma samples) was included as a negative control because it should not contain coagulation proteins (eg, fibrinogen). Nonpurified pooled equine serum also was included to detect nonspecific protein binding by antifibrinogen antibodies during Western blotting.

Gels were rinsed with deionized water to remove remaining SDS and then stained using Coomassie Blue (Bio-Safe Coomassie Stain, Bio-Rad), according to the manufacturer’s protocol. Densitometry scanning was performed (ChemIDoc XRS+ system, Bio-Rad) to convert the optical densities of the obtained gel bands into an electrophoretogram. Molecular
weight estimation of protein bands was performed using a point-to-point semilog regression method (ImageLab 6.0.1 software, Bio-Rad). The proportion of each fibrinogen fraction was calculated from densitometric scans. The LMW- and LMW\(^0\)-Fb were grouped together as LMW/LMW\(^0\)-Fb, as described in previous studies,\(^{16,17}\) because of poor separation of these bands and low proportions of LMW\(^0\)-Fb.

2.4 | Western blotting

Western blotting was performed as previously described\(^{18,19}\) to confirm that the purified, nonreduced proteins were fibrinogen and that the purified, reduced proteins were fibrinogen polypeptide subunits. Quantities of loaded protein were adjusted based on preliminary Western blots to optimize visibility. Proteins were transferred from the SDS-PAGE gel to a polyvinylidene difluoride (PVDF) membrane using a rapid transfer system (Trans-Blot Turbo Transfer System, Bio-Rad) and ready-to-assemble transfer kits (Trans-Blot Turbo Midi PVDF Transfer packs, Bio-Rad). Protein transfer was performed at 1.3 A, up to 25 V, for 15 minutes for nonreduced samples or for 7 minutes for reduced samples. After protein transfer, membranes were rinsed, and then soaked in washing buffer (tris-buffered saline [TBS] with 0.1% Tween 20, Chem-supply, Port Adelaide, Australia). Nonspecific antibody binding was minimized by blocking membranes with TBS and 5% skim milk for 1 hour at room temperature. Membranes then were incubated with 1 mg/mL sheep anti-human fibrinogen IgG antibodies conjugated to horseradish peroxidase (Affinity Biologicals, Ancaster, Canada) at a 1 : 10 000 dilution for 1 hour at room temperature. After removal of
the antibody solution and washing, enhanced chemiluminescence (ECL) substrate (Clarity Western ECL Substrate, Bio-Rad) was added for generation of a chemiluminescent signal. Membranes were imaged using chemiluminescent and colorimetric settings to allow visualization of both samples and molecular mass markers in a single merged image (ChemiDoc XRS+ system and ImageLab 6.0.1 software, Bio-Rad).

To intensify the Aα chain chemiluminescent signal, SDS-PAGE and Western blotting were repeated on the reduced sample under
identical conditions to those described above but using a 3% to 8% tris-acetate gel and tris-acetate SDS running buffer (NuPAGE Tris-Acetate Protein Gels and SDS Running Buffer, Thermo Scientific). The horse protein lane was excised from the PDVF membrane before chemiluminescent signal detection.

2.5 Confirmation of findings by centrifugal filtration

To confirm that the lower molecular weight bands corresponding to LMW/LMW-Fb identified on SDS-PAGE were not an in vitro artifact of chemical manipulation associated with the fibrinogen purification procedure, 500 μL of citrated plasma from a single horse was filtered using a centrifugal device (Amicon Ultra 0.5 mL 100 kDa Centrifugal Filter, Merck, Darmstadt, Germany). The filtration device was centrifuged at 14 000g for 10 minutes, with mixing of the sample by gentle pipetting at 5 minutes. The concentrate obtained then was subjected to electrophoresis in a non-reduced form followed by Western blotting as described above.

2.6 Liquid chromatography-tandem mass spectrometry

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to further confirm that the 2 isolated nonreduced protein bands were fibrinogen. Protein bands corresponding to HMW-Fb and LMW-Fb were excised from the gel and prepared for LC-MS/MS based
on previously described protocols. Liquid chromatography-tandem mass spectrometry was performed using a hybrid quadrupole-Orbitrap mass spectrometer (Q Exactive Mass Spectrometer, Thermo Scientific) fitted with nanoflow reversed-phase-high performance liquid chromatography (HPLC; Dionex Ultimate 3000 RSLC, Thermo Scientific) for separation of peptides.

Raw data files from LC-MS/MS were searched against the Equus caballus protein reference proteomes (UniProt Proteome ID: UP000002281) using MaxQuant-Andromeda (version 1.6.7.0). The false discovery rate (FDR) was set at 0.01 for both peptides and proteins. Andromeda results were filtered to exclude potential contaminants, and include only proteins with scores >20 (based on our previously selected FDR of 0.01) to exclude low confidence identifications.

### 3 | RESULTS

#### 3.1 | Gel electrophoresis of purified horse protein

Gel electrophoresis of nonreduced samples showed separation of purified horse protein into 2 distinct bands of approximately 377 and 318 kDa (Figure 1), with a small shoulder at 289 kDa visible only on densitometry scanning (Figure 2). Approximate proportions were 74% HMW-Fb, and 26% LMW-Fb and LMWγ-Fb.

Gel electrophoresis of reduced samples showed separation of the purified equine fibrinogen into 3 distinct bands of approximately 74, 56, and 48 kDa (Figure 3), similar to reported molecular weights of horse α, β, and γ chains, respectively. For both nonreduced and reduced samples, no protein bands were visible in the lane containing purified pooled equine serum.

Gel electrophoresis of the nonreduced sample obtained by centrifugal plasma filtration showed 2 distinct bands of similar molecular weights as those obtained using the modified Vila method (Figure S1).
4 | DISCUSSION

We found fibrinogen heterogeneity in the plasma of a small group of healthy horses, with 2 major fractions identified. Ours is the first study to isolate lower molecular weight fibrinogen fractions in a non-human species and describes a technique for purification of these proteins from equine plasma. The molecular weights of HMW-Fb and LMW-Fb in horses were found to be slightly higher than those described in humans, but fraction proportions were remarkably similar to those found in previous studies of healthy humans. The small shoulder observed at 289 kDa on densitometry scanning of the non-reduced pooled equine fibrinogen gel is presumed to correspond to LMW-Fb, given its similar molecular weight to human LMW fibrinogen. However, because of its low proportion, further analysis by Western blotting or mass spectrometry was not performed and thus we cannot be sure that this protein truly is fibrinogen.

Reduced purified equine fibrinogen had poor Aα chain antibody binding on the Western blot, but mass spectrometry identified the presence of fibrinogen Aα chain in purified samples, supporting the identity of this protein. The poor antibody binding likely reflects the use of anti-human, rather than anti-horse fibrinogen antibodies. The suboptimal avidity of anti-human fibrinogen antibody for the horse Aα chain may reflect the difference in molecular weight of this protein in horses (74 kDa) versus humans (66 kDa) on gel electrophoresis, which suggests differences in structure. When comparing the percentage identity of the various fibrinogen chains between humans and horses using a Needleman-Wunsch global alignment, the percentage identity of Bβ and γ chains was 82% (accession XP_003364583.1 and AAA18024.2, NCBI protein) and 84% (accession XP_001914833.2 and AAB59531.1, NCBI protein), respectively, but Aα chains showed only 44% identity (accession XP_005607860 and AAA17055.1, NCBI protein). Unfortunately, anti-horse fibrinogen antibodies are not currently commercially available.

As suggested earlier, it is uncertain if the lower molecular weight fibrinogen fractions truly exist in vivo, and one could speculate that the lower molecular weight fibrinogen fractions identified in our study are simply an artifact of poor sample preservation. We attempted to limit in vitro degradation by replicating methodology of studies of humans as closely as possible, ensuring timely processing (ie, cold centrifugation within 30 minutes of collection followed by immediate purification) and using freshly prepared aprotinin as an antiprotease. The electrophoretogram and Western blot obtained from centrifugal filtration of plasma indicate that the LMW/LMW-Fb fractions are unlikely to be artifacts of chemical manipulation of fibrinogen using the modified Vila method. The third band (approximately 350 kDa) observed in the horse lane of the PAGE gel after centrifugal filtration also was present in unfiltered serum, and was not visible on Western blots, thus this band likely represents a nonfibrinogen protein. Regardless, whether lower molecular weight fractions are products of in vivo or in vitro degradation, they are likely to be present in samples presented to clinical pathology laboratories for processing, and thus could be the cause of differences in total fibrinogen between citrated and EDTA-anticoagulated equine plasma observed in some horses in our laboratory.

3.3 | Liquid chromatography with tandem mass spectrometry of purified horse protein

Liquid chromatography with tandem mass spectrometry of proteins bands corresponding to HMW-Fb and LMW-Fb both generated spectra consistent with Aα, Bβ, and γ fibrinogen subunits, among several other proteins. Of all the suggested proteins, the Aα, Bβ, and γ fibrinogen subunits had the highest numbers of razor and unique peptides, highest sequence coverage, and highest protein scores and sequencing events (MS/MS counts; Table S1).
Mass spectrometry identified several nonfibrinogen proteins in both the 379 and 318 kDa protein bands, which is not surprising considering the method of protein purification (multistep precipitation rather than immunologic methods) and the high sensitivity of mass spectrometry. Although absolute quantification of proteins was not performed, fibrinogen proteins had much higher razer and unique peptide counts, and higher sequence coverage than did nonfibrinogen proteins, which suggests a higher likelihood that fibrinogen proteins were present. In addition, their markedly higher MS/MS counts suggest that they were probably the most abundant protein in these lanes.31

Our study was limited by the low number of healthy horses, samples from which were pooled together rather than run individually for the first part of this study. This approach was used to facilitate rapid sample processing and limit protein degradation. Considering that the aim of our study was to identify the existence of fibrinogen heterogeneity in horses, rather than to determine RIs for fraction proportions, pooling was considered most suitable. It remains possible that fibrinogen heterogeneity may not occur in all horses, because only a small group of pooled samples was evaluated.

Additional studies are needed to determine if the difference between EDTA and citrated plasma fibrinogen concentrations in horses is caused by the presence of lower molecular weight fibrinogen, and if this can be corrected with the addition of magnesium chloride to EDTA samples, as has been done in humans.9 Although the proportions of fibrinogen fractions in our study are similar to those described in humans, ours was not a RI study and larger scale studies are required to determine the true prevalence of fibrinogen heterogeneity in horses and the relative fraction proportions in health.

The modified Vila method of fibrinogen purification is not commercially feasible, because it is time- and labor-intensive. Although not commercially feasible, the modified Vila method may be suitable for research purposes, and for development of a more time- and labor-efficient alternative, such as immunoassay.

In conclusion, we identified the existence of fibrinogen heterogeneity in horses, which, with additional studies, could be determined to have important implications for how fibrinogen concentrations are analyzed and interpreted in this species.

ACKNOWLEDGMENT

Funding for this study was provided by the University of Melbourne. Preliminary results from this study were presented as a poster at the joint European College of Veterinary Pathologists/European Society of Veterinary Pathology/European College of Veterinary Clinical Pathology/European Society of Veterinary Clinical Pathology Annual Congress, Arnhem, Netherlands, September 2019. The authors thank Vera Ignotovic of the Murdoch Children's Research Institute, Melbourne for her kind donation of antibodies for this study. We also thank Dr Swati Varshney and Associate Professor Nicholas Williamson at the Melbourne Mass Spectrometry and Proteomics facility at The Bio21 Molecular Science and Biotechnology Institute at The University of Melbourne for her proteomics expertise, and Fiona Armour, Amanda Hobb, Deborah Kirkham, and Daniel Pilbeam of the Clinical Pathology Laboratory at UVet for their assistance with sample analysis.

CONFLICT OF INTEREST DECLARATION

Authors declare no conflict of interest.

OFF-LABEL ANTIMICROBIAL DECLARATION

Authors declare no off-label use of antimicrobials.

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION

Ethics approval was granted for the collection of small volumes of blood for research purposes from the University of Melbourne equine teaching herd (1714380.2).

HUMAN ETHICS APPROVAL DECLARATION

Authors declare human ethics approval was not needed for this study.

ORCID

Elise B. Russell https://orcid.org/0000-0001-7583-5465

REFERENCES

1. Weisel JW, Dempfle CH. Fibrinogen structure and function. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012:254-271.
2. Holm B, Godal HC. Quantitation of the three normally occurring plasma fibrinogens in health and during so-called “acute phase” by SDS electro-phoresis of fibrin obtained from EDTA-plasma. Thromb Res. 1984;35:279-290.
3. Holm B, Nilsen DW, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res. 1985;37:165-176.
4. Adler G, Duchsinski T, Jasinska A, Piotrowska U. Fibrinogen fractions in the third trimester of pregnancy and in puerperium. Thromb Res. 2000;97:405-410.
5. Holm B, Nilsen DWT, Godal HC. Evidence that low molecular fibrinogen (LMW) is formed in man by degradation of high molecular weight fibrinogen (HMW). Thromb Res. 1986;41:879-884.
6. Nakashima A, Sasaki S, Miyazaki K, Miyata T, Iwanaga S. Human fibrinogen heterogeneity; the COOH-terminal residues of defective A alpha chains of fibrinogen II. Blood Coagul Fibrinolysis. 1992;3:361-370.
7. Jensen T, Halvorsen S, Godal HC, Sandset PM, Skjønsberg OH. Discrepancy between fibrinogen concentrations determined by clotting rate and clotability assays during the acute-phase reaction. Thromb Res. 2000;100:397-403.
8. Lipinski I, Lipinski B, Gurewich V, Hoffman KD. Fibrinogen heterogeneity in cancer, in occlusive vascular disease, and after surgical procedures. Am J Clin Pathol. 1976;66:958-966.
9. Lipinski I, Lipinski B. Effect of magnesium on fibrin formation from lower molecular weight (LMW) fibrinogen. Magnes Res. 2000;13:233-237.
10. Reganone E, Vila V, Ferrando F, et al. Elevated high molecular weight fibrinogen in plasma is predictive of coronary ischemic events after acute myocardial infarction. Thromb Haemost. 1999;82:1403-1405.
11. Claus A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des fibrinogens. Acta Haematol. 1957;17:237-246.
12. Millar HR, Simpson JC, Stalker AL. An evaluation of the heat precipitation method for plasma fibrinogen estimation. J Clin Pathol. 1971;24:827-830.
13. Mackie IJ, Kitchen S, Machin SJ, Lowe GDO. Guidelines on fibrinogen assays. Br J Haematol. 2003;121:396-404.
14. Vila V, Regañón E, Llopis F, Aznar J. A rapid method for isolation of fibrinogen from human plasma by precipitation with polyethylene glycol 6,000. Thromb Res. 1985;39:651-656.
15. Smith PK, Krohn RI, Hernandez GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76-85.
16. Manten GTR, Sikkema JM, Franx A, et al. Increased high molecular weight fibrinogen in pre-eclampsia. Thromb Res. 2003;111:143-147.
17. Manten G, Franx A, Sikkema JM, et al. Fibrinogen and high molecular weight fibrinogen during and after normal pregnancy. Thromb Res. 2004;114:19-23.
18. Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific differences in binding of heparin to plasma proteins. J Thromb Haemost. 2010;8:1290-1294.
19. Ignjatovic V, Lai C, Summerhayes R, et al. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults. PLoS One. 2011;6:e17213.
20. Goodman JK, Zampronio CG, Jones AME, Hernandez-Fernaud JR. Updates of the in-gel digestion method for protein analysis by mass spectrometry. Proteomics. 2018;18:e1800236.
21. Rosenfeld J, Capdevielle J, Gullomet JC, Ferrara P. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal Biochem. 1992;203:173-179.
22. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 2006;1:2856-2860.
23. Gundy RL, White MY, Murray CI, et al. Preparation of proteins and peptides for mass spectrometry analysis in a bottom-up proteomics workflow. Curr Protoc Mol Biol. 2009;90:10.25.1-10.25.23. https://doi.org/10.1002/0471142772.mb1025s88.
24. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26:1367-1372.
25. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011;10:1794-1805.
26. Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc. 2016;11:2301-2319.
27. Hashimoto M, Nambo Y, Kondo T, Watanabe K, Orino K. A study on the presence of ferritin-binding proteins in fetal horse plasma. J Equine Sci. 2011;22:1-7.
28. Needleman SB, Wunsch CD. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. 1970;48:443-453.
29. Madden T. The BLAST sequence analysis tool. In: Beck J, Benson D, Coleman J, et al., eds. The NCBI Handbook [Internet]. 2nd ed. Bethesda, MD: National Centre for Biotechnology Information (US); 2013. https://www.ncbi.nlm.nih.gov/books/NBK143764/.
30. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389-3402.
31. Liu H, Sadygov RG, Yates JR. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem. 2004;76:4193-4201.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Russell EB, Courtman NF, Santos LL, Tennent-Brown BS. Fibrinogen heterogeneity in horses. J Vet Intern Med. 2021;35:1131–1139. https://doi.org/10.1111/jvim.16065
Author/s:
Russell, EB; Courtman, NF; Santos, LL; Tennent-Brown, BS

Title:
Fibrinogen heterogeneity in horses

Date:
2021-02-19

Citation:
Russell, E. B., Courtman, N. F., Santos, L. L. & Tennent-Brown, B. S. (2021). Fibrinogen heterogeneity in horses. JOURNAL OF VETERINARY INTERNAL MEDICINE, 35 (2), pp.1131-1139. https://doi.org/10.1111/jvim.16065.

Persistent Link:
http://hdl.handle.net/11343/274138

File Description:
Published version

License:
CC BY-NC